Normal view MARC view ISBD view

Brachytherapy boost: A novel approach for epiglottic carcinoma

In Brachytherapy
Contributor(s): Jamema SV | Mahantshetty UM | Pathak KA | drbhalavat@yahoo.com <drbhalavat@yahoo.com> | Bhalavat RL.
Material type: materialTypeLabelArticleSeries: Vol 6 Issues 3.Publisher: 2007Description: 212-217.Subject(s): India | Brachytherapy | Implant | Interstitial radiation | Supraglottic cancer | Epiglottic cancer | DDC classification: In: BrachytherapySummary: Purpose Epiglottic (epilaryngeal) carcinoma has been treated conventionally by radical external beam radiotherapy or partial laryngectomy. The aim of this study is to evaluate the role of brachytherapy boost as a novel approach for lingual epiglottic lesions. Methods and materials Twenty-three patients with T23N01 lingual epiglottic carcinoma (SCC) were treated with curative intent between January 1990 and December 2001 using low dose rate interstitial 192Ir implant boost, moderate dose of 25Gy at 0.5cm (mean dose rate, 50.5cGy/h) 3 weeks after moderate dose of external beam radiotherapy (mEBRT) of 46Gy/23#/2831d. Results Complete response after mEBRT was observed in 18 of the 23 patients (78%) and partial response was seen in 5 of the 23 patients (22%). After implant, all patients had complete response. Locoregional control was seen in 19 of the 23 patients (82.6%). Two patients developed distant metastases. Disease-free survival and overall survival at 5 years were 68.3% and 66.7%, respectivel
Tags from this library: No tags from this library for this title. Add tag(s)
Log in to add tags.
    average rating: 0.0 (0 votes)
Item type Current location Call number Status Date due Barcode
Articles Articles Tata Memorial Hospital
Available AR6940

Purpose
Epiglottic (epilaryngeal) carcinoma has been treated conventionally by radical external beam radiotherapy or partial laryngectomy. The aim of this study is to evaluate the role of brachytherapy boost as a novel approach for lingual epiglottic lesions.

Methods and materials
Twenty-three patients with T23N01 lingual epiglottic carcinoma (SCC) were treated with curative intent between January 1990 and December 2001 using low dose rate interstitial 192Ir implant boost, moderate dose of 25Gy at 0.5cm (mean dose rate, 50.5cGy/h) 3 weeks after moderate dose of external beam radiotherapy (mEBRT) of 46Gy/23#/2831d.

Results
Complete response after mEBRT was observed in 18 of the 23 patients (78%) and partial response was seen in 5 of the 23 patients (22%). After implant, all patients had complete response. Locoregional control was seen in 19 of the 23 patients (82.6%). Two patients developed distant metastases. Disease-free survival and overall survival at 5 years were 68.3% and 66.7%, respectivel

There are no comments for this item.

Log in to your account to post a comment.

Powered by Koha